Vionelix Pharmaceuticals, Inc.

Platform for safe and effective RNA-based direct a...

Raising $5,000,000

You can request access to view the full terms of this fundraise.

Request Access

Vionelix Pharmaceuticals, Inc.:
Fast Facts​

We are developing an Antisense Oligonucleotide (ASO) platform for safe and effective direct antiviral treatments where only limited therapies are available. Our novel platform allows us to target a range of infectious diseases and to effectively address the problem of viral mutations, which has previously made the development of antiviral drugs challenging.

An Inefficiency and Efficacy Problem

Viral diseases are a devastating global problem, as we’ve seen recently with COVID-19.

Unfortunately, antivirals, antibiotics, and vaccines all lose their efficacy as viruses and bacteria develop mutations to become resistant to them. 

Vionelix Targets the
Cause of Disease 

Our mission is to alleviate the burden of infectious diseases on humanity.

We have developed an Antisense Oligonucleotide (ASO) platform for safe and effective direct antiviral treatments where only limited therapies are available.

Our platform uses the well-established ASO technology plus a novel and proprietary approach to target viral protein synthesis. Our drugs are designed to counteract the loss of treatment efficacy due to viral mutations.

Our drugs are designed to treat COVID-19, Hepatitis C, AIDS, and potentially other diseases and illnesses.

Key Features 

Efficacious Drugs: Our drugs are designed to be efficacious against viral mutations. 

Universally Accessible Treatments: The drug profiles are designed to provide greater accessibility, especially for more vulnerable populations in the regions with greater need. 

Traction & Accomplishments 

Meet The Team 

Boris A. Maslov
Over the last 30 years, Boris accumulated extensive experience in building, developing and managing companies in cutting-edge industries, including biotech, chemical, nanotechnology, and advanced manufacturing. He led executive teams through successful public listings and other exits strategies.

Emre Amirak
Emre has a biochemical and medical background in a variety of drug classes, including RNA and gene therapies and ASO drugs. He has been senior medical leadership at Akcea, Sanofi Genzyme, and Orphazyme, and was instrumental in Waylivra® and Tegsedi® development. Emre is a member of the British Pharmacopoeia Expert Advisory Group on Biological and Biotechnological Products.

Julia Campbell
Julia has over 15 years of executive leadership in pharmaceutical and CRO-side drug development and extensive expertise in building, developing and growing international businesses, both in private and large-cap public company settings in clinical development and market access sectors. She has substantial experience in investor-side biotech funding. 

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.